Get the Stockscreener App
1.095
1.35%
-0.015
Renovorx Inc stock is traded at $1.095, with a volume of 331.47K.
It is down -1.35% in the last 24 hours and down -17.05% over the past month.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
See More
Previous Close:
$1.11
Open:
$1.13
24h Volume:
331.47K
Relative Volume:
0.63
Market Cap:
$40.13M
Revenue:
-
Net Income/Loss:
$-9.16M
P/E Ratio:
-1.9211
EPS:
-0.57
Net Cash Flow:
$-8.75M
1W Performance:
-4.78%
1M Performance:
-17.05%
6M Performance:
+9.50%
1Y Performance:
+7.35%
1-Day Range:
$1.05
$1.13
1-Week Range:
$0.9834
$1.175
52-Week Range:
$0.75
$1.6899
Renovorx Inc Stock (RNXT) Company Profile
Name
Renovorx Inc
Sector
Industry
Phone
408-800-2649
Address
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
1.095 | 40.68M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.08 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.99 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.26 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.85 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.78 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Renovorx Inc Stock (RNXT) Latest News
Tick level data insight on RenovoRx Inc. volatilityWeekly Volume Report & Entry and Exit Point Strategies - newser.com
Is RenovoRx Inc. stock attractive for income investorsMarket Movers & Advanced Swing Trade Entry Plans - newser.com
Using AI based signals to follow RenovoRx Inc.2025 Winners & Losers & Weekly Return Optimization Alerts - newser.com
Does RenovoRx Inc. fit your quant trading modelMarket Risk Report & Capital Efficiency Focused Ideas - newser.com
What analyst consensus says on RenovoRx Inc. stock2025 Pullback Review & Accurate Intraday Trading Signals - newser.com
Can RenovoRx Inc. stock deliver consistent earnings growth2025 Trading Recap & AI Enhanced Trading Signals - newser.com
Intraday pattern recognizer results for RenovoRx Inc.2025 Pullback Review & Long Hold Capital Preservation Tips - newser.com
Is RenovoRx Inc. stock supported by innovation pipelineTrade Ideas & Verified Technical Trade Signals - newser.com
Should I hold or sell RenovoRx Inc. stock in 20252025 Support & Resistance & Fast Entry Momentum Trade Alerts - newser.com
Why RenovoRx Inc. stock remains on watchlists2025 Dividend Review & Risk Managed Investment Strategies - newser.com
How to integrate RenovoRx Inc. into portfolio analysis toolsQuarterly Trade Review & Short-Term High Return Strategies - newser.com
Will RenovoRx Inc. stock attract ESG investorsAnalyst Upgrade & Advanced Swing Trade Entry Plans - newser.com
Evaluating RenovoRx Inc. with trendline analysisJuly 2025 Short Interest & Long-Term Growth Plans - newser.com
First Patient Treated in RenovoCath Clinical Trial - Medical Product Outsourcing
RenovoRx’s PanTheR Registry Trial: A New Frontier in Tumor Treatment - TipRanks
RenovoRx’s Innovative Approach in Pancreatic Cancer Treatment: A Clinical Study Update - TipRanks
RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET - The Manila Times
RenovoRx (Nasdaq: RNXT) to host Q3 2025 call; RenovoCath and Phase III TIGeR-PaC - Stock Titan
Renovorx Inc Stock (RNXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):